文献速递脑血管病

替奈普酶在急性缺血性卒中治疗中不劣于阿替普酶:5项随机试验的荟萃分析

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.
PubMed 文献 · Stroke · 2019-07-18

该荟萃分析纳入5项随机对照试验共1585例急性缺血性卒中患者,比较替奈普酶(TNK)与阿替普酶(ALT)的疗效与安全性。主要终点3个月无残疾(mRS 0-1)粗累积率TNK 57.9% vs ALT 55.4%,风险差4%(95%CI -1% to 8%),下限落在预设非劣效界值内。结论支持TNK在急性缺血性卒中治疗中不劣于ALT,为指南推荐TNK作为ALT替代方案提供了正式依据。

要点

  • TNK在3个月无残疾结局上不劣于ALT,风险差4%(95%CI -1% to 8%)。
  • 功能独立(mRS 0-2)风险差2%(95%CI -3% to 6%),支持非劣效。
  • 安全性终点事件率较低致把握度下降,但点估计与非劣效一致。

核心结论

  • 累积临床试验数据提供强证据表明TNK在急性缺血性卒中治疗中不劣于ALT。
  • 研究结果为近期指南将TNK视为ALT替代方案提供了正式支持。

研究设计与样本

  • 系统文献检索与正式荟萃分析,按PRISMA指南并 adapted to 非劣效分析。
  • 纳入5项随机对照试验,共1585例患者(TNK 828例,ALT 757例)。
  • 平均年龄70.8岁,男性58.5%,基线NIHSS平均7.0,发病至治疗开始平均148分钟。
  • ALT患者均接受标准0.9 mg/kg剂量;TNK剂量为0.1 mg/kg占6.8%、0.25 mg/kg占24.6%、0.4 mg/kg占68.6%。

主要发现

  • 主要终点3个月无残疾(mRS 0-1)粗累积率:TNK 57.9% vs ALT 55.4%。
  • 随机效应荟萃分析风险差4%(95%CI -1% to 8%),下限在预设非劣效界值内。
  • 功能独立(mRS 0-2)粗率TNK 71.9% vs ALT 70.5%,风险差2%(95%CI -3% to 6%)。
  • mRS移位分析共同比值比1.21(95%CI 0.93-1.57)。
  • 安全性终点事件率较低致把握度下降,但点估计与非劣效一致。

关键数值与推荐

  • 主要终点为非劣效分析,预设非劣效界值未在原文摘要中给出具体数值。
  • TNK剂量在不同试验中为0.1、0.25或0.4 mg/kg,ALT标准剂量为0.9 mg/kg。

临床怎么用

  • 对于急性缺血性卒中溶栓治疗,TNK可作为ALT的替代选择。
  • 临床决策时可参考本荟萃分析的非劣效结果,结合指南推荐个体化选用TNK。

局限性

  • 安全性终点事件率较低,导致统计把握度下降。
  • 原文摘要未报告各试验间异质性、偏倚风险等详细局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- TNK (tenecteplase), a newer fibrinolytic agent, has practical delivery advantages over ALT (alteplase) that would make it a useful agent if noninferior in acute ischemic stroke treatment outcome. Accordingly, the most recent US American Heart Association/American Stroke Association acute ischemic stroke guideline recognized TNK as an alternative to ALT, but only based on informal consideration, rather than formal meta-analysis, of completed randomized control trials. Methods- Systematic literature search and formal meta-analysis were conducted per PRISMA guidelines (Preferred Reporting Items for Systemic Reviews and Meta-Analyses), adapted to noninferiority analysis. The primary outcome of freedom from disability (modified Rankin Scale score, 0-1) outcome at 3 m, and additional efficacy and safety outcomes, were analyzed. Results- Systematic search identified 5 trials enrolling 1585 patients (828 TNK, 757 ALT). Across all trials, mean age was 70.8, 58.5% male, baseline National Institutes of Health Stroke Scale mean 7.0, and time from last known well to treatment start mean 148 minutes. All ALT patients received standard 0.9 mg/kg dosing, while TNK dosing was 0.1 mg/kg in 6.8%, 0.25 mg/kg in 24.6%, and 0.4 mg/kg in 68.6%. For the primary end point, crude cumulative rates of disability-free (modified Rankin Scale score, 0-1) 3 m outcome were TNK 57.9% versus ALT 55.4%. Informal, random-effects meta-analysis, the risk difference was 4% (95% CI, -1% to 8%). The lower 95% CI bound fell well within the prespecified noninferiority margin. Similar results were seen for the additional efficacy end points: functional independence (modified Rankin Scale score, 0-2): crude TNK 71.9% versus ALT 70.5%, risk difference 2% (95% CI, -3% to 6%); and modified Rankin Scale shift analysis, common odds ratio 1.21 (95% CI, 0.93-1.57). For safety end points, lower event rates reduced power, but point estimates were also consistent with noninferiority Conclusions- Accumulated clinical trial data provides strong evidence that TNK is noninferior to ALT in the treatment of acute ischemic stroke. These findings provide formal support for the recent guideline recommendation to consider TNK an alternative to ALT.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke. 2019. PMID: 31318627. doi:10.1161/STROKEAHA.119.025080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。